# EDGAR Filing Document

**Accession Number:** 0001124105
**File Stem:** 0000899243-23-000968
**Filing Date:** 2023-1
**Character Count:** 15440
**Document Hash:** 15204edf9e3b1e4d0d6ae051cf02975f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000899243-23-000968.hdr.sgml**: 20230105

**ACCESSION NUMBER**: 0000899243-23-000968

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20221226

**FILED AS OF DATE**: 20230105

**DATE AS OF CHANGE**: 20230105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GNI Group Ltd.
- **CENTRAL INDEX KEY:** 0001958461

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51173
- **FILM NUMBER:** 23511297

**BUSINESS ADDRESS:**
- **STREET 1:** NIHONBASHI-HONCHO YS BLDG 3F
- **STREET 2:** 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-0023
- **BUSINESS PHONE:** 81-3-6214-3600

**MAIL ADDRESS:**
- **STREET 1:** NIHONBASHI-HONCHO YS BLDG 3F
- **STREET 2:** 2-2-2 NIHONBASHI-HONCHO, CHUO-KU
- **CITY:** TOKYO
- **STATE:** M0
- **ZIP:** 103-0023
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** GNI Hong Kong Ltd
- **CENTRAL INDEX KEY:** 0001958509

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51173
- **FILM NUMBER:** 23511296

**BUSINESS ADDRESS:**
- **STREET 1:** 12/F ELITE CENTRE
- **STREET 2:** 22 HUNG TO ROAD
- **CITY:** KWUN TONG KL
- **STATE:** K3
- **ZIP:** 0000
- **BUSINESS PHONE:** 81-3-6214-3600

**MAIL ADDRESS:**
- **STREET 1:** 12/F ELITE CENTRE
- **STREET 2:** 22 HUNG TO ROAD
- **CITY:** KWUN TONG KL
- **STATE:** K3
- **ZIP:** 0000
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CATALYST BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001124105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 562020050
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 710
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-871-0761

**MAIL ADDRESS:**
- **STREET 1:** 611 GATEWAY BLVD., SUITE 710
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGACEPT INC
- **DATE OF NAME CHANGE:** 20000919

## Exhibit 24.1

```
<PRE>
                                POWER OF ATTORNEY

        Know all by these presents that the undersigned hereby constitutes and
appoints each of Ying Luo, Thomas Wilson Eastling, Ruoyu Chen, Branden Berns,
and Ryan Murr, and any of their substitutes, signing singly, as the
undersigned's true and lawful attorney-in-fact to:

1.  prepare, execute in the undersigned's name and on the undersigned's behalf,
    and submit to the U.S. Securities and Exchange Commission (the "SEC") a
    Form ID, including amendments thereto, and any other document necessary or
    appropriate to obtain codes, passwords, and passphrases enabling the
    undersigned to make electronic filings with the SEC of reports require by
    the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

2.  execute for and on behalf of the undersigned, in the undersigned's capacity
    as a director and/or officer of Catalyst Biosciences, Inc. (the "Company"),
    Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities
    Exchange Act of 1934 and the rules thereunder;

3.  do and perform any and all acts for and on behalf of the undersigned which
    may be necessary or desirable to complete and execute any such Form 3, 4,
    or 5, complete and execute any amendment or amendments thereto, and timely
    file such form with the SEC and any securities exchange or similar
    authority; and

4.  take any other action of any type whatsoever in connection with the
    foregoing which, in the opinion of such attorney-in-fact, may be of benefit
    to, in the best interest of, or legally required by, the undersigned, it
    being understood that the documents executed by such attorney-in-fact on
    behalf of the undersigned pursuant to this Power of Attorney shall be in
    such form and shall contain such terms and conditions as such attorney-in-
    fact may approve in such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned also ratifies hereby any
action previously taken by each attorney-in-fact that would have been
authorized by this power of attorney if it has been in effect at the time such
action was taken. The undersigned acknowledges that each attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of December 26, 2022.

                                   GNI GROUP LTD.

                                   By: /s/ Ying Luo
                                       ---------------------------------------
                                   Name: Ying Luo
                                   Title: President and Chief Executive Officer

</PRE>
```

## Exhibit 24.2

```
<PRE>
                                POWER OF ATTORNEY

        Know all by these presents that the undersigned hereby constitutes and
appoints each of Ying Luo, Thomas Wilson Eastling, Ruoyu Chen, Branden Berns,
and Ryan Murr, and any of their substitutes, signing singly, as the
undersigned's true and lawful attorney-in-fact to:

1.  prepare, execute in the undersigned's name and on the undersigned's behalf,
    and submit to the U.S. Securities and Exchange Commission (the "SEC") a
    Form ID, including amendments thereto, and any other document necessary or
    appropriate to obtain codes, passwords, and passphrases enabling the
    undersigned to make electronic filings with the SEC of reports require by
    the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

2.  execute for and on behalf of the undersigned, in the undersigned's capacity
    as a director and/or officer of Catalyst Biosciences, Inc. (the "Company"),
    Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities
    Exchange Act of 1934 and the rules thereunder;

3.  do and perform any and all acts for and on behalf of the undersigned which
    may be necessary or desirable to complete and execute any such Form 3, 4,
    or 5, complete and execute any amendment or amendments thereto, and timely
    file such form with the SEC and any securities exchange or similar
    authority; and

4.  take any other action of any type whatsoever in connection with the
    foregoing which, in the opinion of such attorney-in-fact, may be of benefit
    to, in the best interest of, or legally required by, the undersigned, it
    being understood that the documents executed by such attorney-in-fact on
    behalf of the undersigned pursuant to this Power of Attorney shall be in
    such form and shall contain such terms and conditions as such attorney-in-
    fact may approve in such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that each such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned also ratifies hereby any
action previously taken by each attorney-in-fact that would have been
authorized by this power of attorney if it has been in effect at the time such
action was taken. The undersigned acknowledges that each attorney-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to
comply with Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of December 26, 2022.

                                   GNI HONG KONG LIMITED

                                   By: /s/ Ying Luo
                                       ---------------------------------------
                                   Name: Ying Luo
                                   Title: Director and President

</PRE>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GNI Group Ltd.<br><sub>(Last) (First) (Middle)</sub><br>NIHONBASHI-HONCHO YS BLDG 3F<br>2-2-2 NIHONBASHI-HONCHO, CHUO-KU<br><sub>(Street)</sub><br>TOKYO, M0 103-0023<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>CATALYST BIOSCIENCES, INC. [ CBIO ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-12-26 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>GNI Hong Kong Ltd<br><sub>(Last) (First) (Middle)</sub><br>12/F ELITE CENTRE<br>22 HUNG TO ROAD<br><sub>(Street)</sub><br>KWUN TONG KL, K3 <br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>CATALYST BIOSCIENCES, INC. [ CBIO ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-12-26 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 895217 | D<sup>(1)(2)</sup> |  |
| Common Stock | 5371304 | D<sup>(3)(4)</sup> |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series X Convertible Preferred Stock | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 17630000 | <sup>(5)</sup> | D<sup>(1)(2)</sup> |  |
| Series X Convertible Preferred Stock | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 105770000 | <sup>(5)</sup> | D<sup>(3)(4)</sup> |  |

---

### Footnotes:

(1) These securities are held by GNI Group Ltd. ("GNI Japan").

(2) GNI Hong Kong Ltd. ("GNI HK") disclaims beneficial ownership of the securities held by GNI Japan for purposes of Rule 16a-1(a)(2), except to the extent of its pecuniary interest therein.

(3) These securities are held by GNI HK.

(4) GNI HK, through GNI Japan-affiliated entities, is a wholly-owned subsidiary of GNI Japan. GNI Japan may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the securities held by GNI HK and, therefore, a "ten percent holder" hereunder.

(5) Shares of Series X Convertible Preferred Stock, par value $0.001 per share (the "Preferred Stock"), are convertible into common stock based on the Conversion Ratio and subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for the Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on December 27, 2022), at the holder's election after 5:00 p.m. (New York City time) on the second business day after the date on which the Issuer's stockholders approve the conversion of the Preferred Stock.

**Remarks:**
Exhibit 24.1 - Power of Attorney
Exhibit 24.2 - Power of Attorney

**Signature:** /s/ Branden Berns, Attorney-in-fact for GNI Group Ltd.  
**Date:** 2023-01-05

**Signature:** /s/ Branden Berns, Attorney-in-fact for GNI Hong Kong Ltd.  
**Date:** 2023-01-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**